Table 2.
Ongoing clinical trials by using various anti-HIV-1 antibodies.
| Trial registry identifier | Antibody | Sponsor | Phase | Estimated end date | Number of participants |
|---|---|---|---|---|---|
| NCT04801758 | VRC01 | HIV Vaccine Trials Network | N/A | Jun 2022 | 30 |
| NCT04319367 | 10-1074-LS + 3BNC117-LS | Imperial College London | Phase II | Mar 2025 | 72 |
| NCT04404049 | UB-421 | UBP Greater China (Shanghai) Co., Ltd | Phase II | Jun 2024 | 39 |
| NCT03743376 | UB-421 | United BioPharma | Phase II | Dec2021 | 31 |
| NCT03147859 | vedolizumab | Ottawa Hospital Research Institute | Phase II | Dec2021 | 24 |
| NCT03721510 | PGT121 + VRC07-523LS +/- PGDM1400 | International AIDS Vaccine Initiative | Phase I/IIa | Oct 2022 | 18 |
| NCT03208231 | VRC01 | NIAID | Phase I/II | Feb 2021 | 68 |
| NCT03707977 | VRC01LS + 10-1074 | NIAID | Phase I/II | Oct 2021 | 40 |
| NCT03554408 | 10-1074-LS + 3BNC117-LS | Rockefeller University | Phase I | Jun 2021 | 75 |
| NCT03571204 | 3BNC117 + 10-1074 | NIAID | Phase I | Jun 2021 | 27 |
| NCT03526848 | 3BNC117 + 10-1074 | Rockefeller University | Phase I | Apr 2022 | 26 |
| NCT04250636 | 3BNC117-LS + 10-1074-LS | Rockefeller University | Phase I | Feb 2022 | 10 |
| NCT03374202 | AAV8-VRC07 | NIAID | Phase I | Mar 2027 | 25 |
| NCT03705169 | SAR441236 | NIAID | Phase I | Feb 2022 | 84 |
| NCT02591420 | VRC01 | NIAID | Phase I | Mar 2021 | 24 |
N/A, not applicable.